ECOG-ACRIN EAF151 for Glioblastoma - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
Adults over 18 years of age who
- Have histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
- Have progression of disease assessed by local site using RANO criteria
- Are not pregnant or breast-feeding
What is Involved?
If you agree to be in this study:
All research study participants will be treated for recurrent brain cancer with bevacizumab and will have two advanced perfusion MRI scans.
-- The first advanced MRI will be done just before your treatment starts with bevacizumab,
-- The second advanced MRI will be done between 12 and 25 days after you start your treatment with bevacizumab, within three days prior to your second dose.